SciClone Pharmaceuticals Company Profile (NASDAQ:SCLN)

About SciClone Pharmaceuticals (NASDAQ:SCLN)

SciClone Pharmaceuticals logoSciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SCLN
  • CUSIP: 80862K10
  • Web:
  • Market Cap: $581.93 million
  • Outstanding Shares: 52,191,000
Average Prices:
  • 50 Day Moving Avg: $11.10
  • 200 Day Moving Avg: $10.55
  • 52 Week Range: $8.55 - $11.43
  • Trailing P/E Ratio: 13.75
  • Foreward P/E Ratio: 10.42
  • P/E Growth: 0.84
Sales & Book Value:
  • Annual Revenue: $172.02 million
  • Price / Sales: 3.38
  • Book Value: $4.79 per share
  • Price / Book: 2.33
  • EBITDA: $45.42 million
  • Net Margins: 25.18%
  • Return on Equity: 21.10%
  • Return on Assets: 19.03%
  • Current Ratio: 8.36%
  • Quick Ratio: 7.57%
  • Average Volume: 477,344 shs.
  • Beta: 1.72
  • Short Ratio: 2.34

Frequently Asked Questions for SciClone Pharmaceuticals (NASDAQ:SCLN)

What is SciClone Pharmaceuticals' stock symbol?

SciClone Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCLN."

How were SciClone Pharmaceuticals' earnings last quarter?

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) posted its earnings results on Wednesday, August, 9th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.24 by $0.02. The business had revenue of $44.52 million for the quarter. SciClone Pharmaceuticals had a net margin of 25.18% and a return on equity of 21.10%. View SciClone Pharmaceuticals' Earnings History.

When will SciClone Pharmaceuticals make its next earnings announcement?

SciClone Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for SciClone Pharmaceuticals.

Where is SciClone Pharmaceuticals' stock going? Where will SciClone Pharmaceuticals' stock price be in 2017?

1 brokerages have issued 1 year price targets for SciClone Pharmaceuticals' shares. Their forecasts range from $14.00 to $14.00. On average, they expect SciClone Pharmaceuticals' share price to reach $14.00 in the next twelve months. View Analyst Ratings for SciClone Pharmaceuticals.

Who are some of SciClone Pharmaceuticals' key competitors?

Who are SciClone Pharmaceuticals' key executives?

SciClone Pharmaceuticals' management team includes the folowing people:

  • Jon S Saxe, Independent Chairman of the Board
  • Friedhelm Blobel Ph.D., President, Chief Executive Officer, Director
  • Wilson W. Cheung, Chief Financial Officer, Senior Vice President - Finance, Secretary
  • Hong Zhao, Chief Executive Officer - China Operations
  • Raymond Anthony Low CPA, Vice President - Finance, Controller
  • Lan Xie CPA, Vice President - Finance, China Chief Financial Officer
  • Nancy T. Chang Ph.D., Independent Director
  • Richard James Hawkins, Independent Director
  • Anthony Gregg Lapointe, Independent Director
  • Simon Li, Independent Director

Who owns SciClone Pharmaceuticals stock?

SciClone Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Eqis Capital Management Inc. (0.03%). Company insiders that own SciClone Pharmaceuticals stock include Friedhelm Blobel, Hong Zhao, Lan Xie, Nancy T Chang and Wilson Wai-Shun Cheung. View Institutional Ownership Trends for SciClone Pharmaceuticals.

Who sold SciClone Pharmaceuticals stock? Who is selling SciClone Pharmaceuticals stock?

SciClone Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. Company insiders that have sold SciClone Pharmaceuticals stock in the last year include Friedhelm Blobel, Hong Zhao, Lan Xie and Wilson Wai-Shun Cheung. View Insider Buying and Selling for SciClone Pharmaceuticals.

How do I buy SciClone Pharmaceuticals stock?

Shares of SciClone Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SciClone Pharmaceuticals' stock price today?

One share of SciClone Pharmaceuticals stock can currently be purchased for approximately $11.15.

MarketBeat Community Rating for SciClone Pharmaceuticals (NASDAQ SCLN)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  163
MarketBeat's community ratings are surveys of what our community members think about SciClone Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for SciClone Pharmaceuticals (NASDAQ:SCLN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $14.00 (25.56% upside)
Consensus Price Target History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Price Target History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Analysts' Ratings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/8/2017Maxim GroupReiterated RatingBuy -> HoldLowView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Earnings by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)
Earnings History by Quarter for SciClone Pharmaceuticals (NASDAQ SCLN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017$0.22N/AView Earnings Details
8/9/2017Q2 2017$0.24$0.26$44.52 millionViewN/AView Earnings Details
3/6/2017Q4 2016$0.15$0.12$44.06 millionViewListenView Earnings Details
5/10/2016Q116$0.19$33.60 million$36.50 millionViewListenView Earnings Details
3/10/2016Q415$0.30$41.10 million$42.90 millionViewListenView Earnings Details
11/9/2015Q315$0.12$0.26$40.61 million$42.90 millionViewN/AView Earnings Details
8/10/2015Q215$0.12$0.26$37.27 million$37.90 millionViewListenView Earnings Details
5/11/2015Q414$0.03$0.17$34.00 million$33.60 millionViewListenView Earnings Details
3/11/2015Q4$0.15$0.29$38.93 million$41.43 millionViewN/AView Earnings Details
11/10/2014Q314$0.12$0.17$34.90 million$34.30 millionViewN/AView Earnings Details
8/11/2014Q214$0.10$0.20$33.40 million$32.50 millionViewListenView Earnings Details
5/12/2014Q114$0.08$0.10$32.20 million$26.60 millionViewListenView Earnings Details
3/12/2014Q314$0.15$0.08$38.30 million$32.70 millionViewListenView Earnings Details
11/12/2013Q114$0.15$0.18$39.70 million$35.20 millionViewListenView Earnings Details
8/7/2013Q2 2013$0.11$0.09$33.30 million$29.81 millionViewListenView Earnings Details
4/1/2013Q4 2012$0.12$0.04$35.30 million$33.10 millionViewListenView Earnings Details
11/9/2012Q312$0.21$0.20$43.09 million$40.70 millionViewN/AView Earnings Details
8/8/2012$0.18$0.20ViewN/AView Earnings Details
5/9/2012$0.11$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for SciClone Pharmaceuticals (NASDAQ:SCLN)
Current Year EPS Consensus Estimate: $0.94 EPS
Next Year EPS Consensus Estimate: $1.07 EPS


Dividend History for SciClone Pharmaceuticals (NASDAQ:SCLN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Insider Ownership Percentage: 5.16%
Institutional Ownership Percentage: 72.80%
Insider Trades by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)
Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)
Insider Trades by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2017Hong ZhaoCEOSell30,000$11.00$330,000.00View SEC Filing  
8/16/2017Lan XieVPSell10,000$11.00$110,000.00View SEC Filing  
6/30/2017Friedhelm BlobelCEOSell35,044$11.00$385,484.00View SEC Filing  
6/20/2017Friedhelm BlobelCEOSell70,000$10.91$763,700.00View SEC Filing  
6/12/2017Wilson Wai-Shun CheungCFOSell40,500$10.75$435,375.00View SEC Filing  
6/8/2017Friedhelm BlobelCEOSell39,656$10.52$417,181.12View SEC Filing  
6/6/2017Friedhelm BlobelCEOSell10,300$10.00$103,000.00View SEC Filing  
5/24/2017Friedhelm BlobelCEOSell21,464$9.32$200,044.48View SEC Filing  
5/22/2017Friedhelm BlobelCEOSell18,536$9.44$174,979.84View SEC Filing  
5/11/2017Friedhelm BlobelCEOSell18,226$10.00$182,260.00View SEC Filing  
4/28/2017Friedhelm BlobelCEOSell4,400$10.01$44,044.00View SEC Filing  
4/24/2017Friedhelm BlobelCEOSell40,000$9.56$382,400.00View SEC Filing  
3/22/2017Friedhelm BlobelCEOSell40,000$9.47$378,800.00View SEC Filing  
3/16/2017Lan XieVPSell1,000$9.60$9,600.00View SEC Filing  
3/6/2017Friedhelm BlobelCEOSell3,087$10.30$31,796.10View SEC Filing  
3/3/2017Friedhelm BlobelCEOSell26,913$10.01$269,399.13View SEC Filing  
2/24/2017Friedhelm BlobelCEOSell823$9.71$7,991.33View SEC Filing  
2/23/2017Friedhelm BlobelCEOSell39,177$9.83$385,109.91View SEC Filing  
1/25/2017Friedhelm BlobelCEOSell8,868$10.54$93,468.72View SEC Filing  
1/24/2017Friedhelm BlobelCEOSell61,132$10.44$638,218.08View SEC Filing  
1/5/2017Friedhelm BlobelCEOSell9,600$11.02$105,792.00View SEC Filing  
12/22/2016Friedhelm BlobelCEOSell70,000$10.55$738,500.00View SEC Filing  
11/22/2016Friedhelm BlobelCEOSell70,000$10.22$715,400.00View SEC Filing  
11/14/2016Friedhelm BlobelCEOSell30,000$10.27$308,100.00View SEC Filing  
10/27/2016Friedhelm BlobelCEOSell40,000$9.30$372,000.00View SEC Filing  
10/26/2016Wilson Wai-Shun CheungCFOSell149,962$10.00$1,499,620.00View SEC Filing  
10/17/2016Wilson Wai-Shun CheungCFOSell1,475$10.00$14,750.00View SEC Filing  
8/30/2016Nancy T ChangDirectorSell25,040$10.30$257,912.00View SEC Filing  
8/29/2016Wilson Wai-Shun CheungCFOSell1,872$10.35$19,375.20View SEC Filing  
8/17/2016Friedhelm BlobelCEOSell501,875$10.00$5,018,750.00View SEC Filing  
8/16/2016Wilson Wai-Shun CheungCFOSell7,802$10.62$82,857.24View SEC Filing  
3/28/2016Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  
3/18/2016Friedhelm BlobelCEOSell10,000$9.09$90,900.00View SEC Filing  
3/7/2016Friedhelm BlobelCEOSell20,000$10.01$200,200.00View SEC Filing  
2/26/2016Friedhelm BlobelCEOSell10,000$9.98$99,800.00View SEC Filing  
1/4/2016Friedhelm BlobelCEOSell200$9.01$1,802.00View SEC Filing  
12/28/2015Friedhelm BlobelCEOSell10,000$9.17$91,700.00View SEC Filing  
12/17/2015Friedhelm BlobelCEOSell9,400$9.00$84,600.00View SEC Filing  
12/11/2015Friedhelm BlobelCEOSell600$9.00$5,400.00View SEC Filing  
12/4/2015Friedhelm BlobelCEOSell10,000$9.22$92,200.00View SEC Filing  
12/3/2015Lan XieCFOSell14,166$9.50$134,577.00View SEC Filing  
11/27/2015Friedhelm BlobelCEOSell10,000$9.24$92,400.00View SEC Filing  
11/10/2015Wilson Wai-Shun CheungCFOSell7,803$9.51$74,206.53View SEC Filing  
7/24/2015Friedhelm BlobelCEOSell10,000$9.68$96,800.00View SEC Filing  
7/17/2015Friedhelm BlobelCEOSell10,000$9.72$97,200.00View SEC Filing  
7/10/2015Friedhelm BlobelCEOSell10,000$9.21$92,100.00View SEC Filing  
7/6/2015Friedhelm BlobelCEOSell20,000$10.80$216,000.00View SEC Filing  
6/26/2015Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  
6/19/2015Friedhelm BlobelCEOSell10,000$9.42$94,200.00View SEC Filing  
6/12/2015Chuncai MengVPSell3,007$9.23$27,754.61View SEC Filing  
6/12/2015Friedhelm BlobelCEOSell10,000$9.13$91,300.00View SEC Filing  
6/8/2015Hong ZhaoCEOSell10,000$9.23$92,300.00View SEC Filing  
6/5/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  
6/1/2015Richard J HawkinsDirectorSell4,570$9.27$42,363.90View SEC Filing  
5/29/2015Friedhelm BlobelCEOSell10,000$9.38$93,800.00View SEC Filing  
5/29/2015Richard J HawkinsDirectorSell10,430$9.32$97,207.60View SEC Filing  
5/26/2015Richard J HawkinsDirectorSell11,982$9.44$113,110.08View SEC Filing  
5/22/2015Friedhelm BlobelCEOSell10,000$9.40$94,000.00View SEC Filing  
5/18/2015Chuncai MengVPSell23,660$9.56$226,189.60View SEC Filing  
5/15/2015Lan XieCFOSell26,668$9.20$245,345.60View SEC Filing  
4/24/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  
4/10/2015Friedhelm BlobelCEOSell10,000$9.10$91,000.00View SEC Filing  
3/12/2015Wilson Wai-Shun CheungCFOSell7,803$9.07$70,773.21View SEC Filing  
12/11/2014Richard J HawkinsDirectorSell15,591$8.80$137,200.80View SEC Filing  
9/2/2014Lan XieCFOSell36,468$6.97$254,181.96View SEC Filing  
8/15/2014Nancy T ChangDirectorBuy25,040$6.00$150,240.00View SEC Filing  
5/16/2014Hong ZhaoCEOSell12,500$4.75$59,375.00View SEC Filing  
8/22/2013Min YinVPSell10,938$5.50$60,159.00View SEC Filing  
8/20/2013Min YinVPSell12,500$5.50$68,750.00View SEC Filing  
2/28/2013Friedhelm BlobelCEOBuy3,000$3.86$11,580.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for SciClone Pharmaceuticals (NASDAQ:SCLN)
Latest Headlines for SciClone Pharmaceuticals (NASDAQ:SCLN)
DateHeadline logoTechnical Snapshots for These Drug Makers Stocks -- SciClone Pharma, Synergy Pharma, Novo Nordisk, and United Therapeutics - October 17 at 3:41 PM logo[$$] Investor Group Buys SciClone Pharmaceuticals - October 14 at 7:42 AM logoImpax Laboratories (IPXL) and SciClone Pharmaceuticals (SCLN) Head to Head Review - October 13 at 2:26 AM logoAnalyzing SciClone Pharmaceuticals (SCLN) and Its Competitors - October 12 at 8:08 PM logoNMI Holdings (NMIH) and Axcelis Technologies (ACLS) Set to Join S&P SmallCap 600 - October 12 at 3:54 PM logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCLN-US : October 11, 2017 - October 12 at 9:18 AM logoInnocoll Holdings PLC (INNL) and SciClone Pharmaceuticals (SCLN) Head to Head Comparison - October 10 at 12:12 PM logoETFs with exposure to SciClone Pharmaceuticals, Inc. : October 9, 2017 - October 10 at 6:39 AM logoSciClone Pharmaceuticals, Inc. :SCLN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017 - October 3 at 12:11 PM logoETFs with exposure to SciClone Pharmaceuticals, Inc. : September 28, 2017 - October 3 at 12:11 PM logoSciClone Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCLN) : September 15, 2017 - September 15 at 8:34 AM logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : September 13, 2017 - September 14 at 9:46 AM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SciClone Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 30, 2017 - August 30 at 9:00 AM logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of SciClone Pharmaceuticals, Inc. - SCLN - August 17 at 9:27 PM logoLan Xie Sells 10,000 Shares of SciClone Pharmaceuticals, Inc. (SCLN) Stock - August 16 at 10:44 PM logoHong Zhao Sells 30,000 Shares of SciClone Pharmaceuticals, Inc. (SCLN) Stock - August 16 at 10:26 PM logoSciClone Announces End Of Go-Shop Period With No Parties Designated As Excluded Parties - August 11 at 8:19 AM logoSciClone Pharmaceuticals, Inc. (SCLN) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS - August 10 at 8:40 PM logoSciClone Reports Second Quarter 2017 Financial Results - August 10 at 7:40 AM logoSciClone posts 2Q profit - August 10 at 7:40 AM logoETFs with exposure to SciClone Pharmaceuticals, Inc. : August 4, 2017 - August 4 at 7:59 AM logoInsider Selling: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) CEO Sells 35,044 Shares of Stock - July 3 at 4:35 PM logoSciClone Pharmaceuticals, Inc. (SCLN) Sees Large Decrease in Short Interest - July 1 at 7:06 AM logoINVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of SciClone Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional ... - June 20 at 6:37 AM logoSciClone Pharmaceuticals Inc (SCLN.OQ) - June 16 at 2:08 AM logoWeissLaw LLP: The Proposed Acquisition of SciClone Pharmaceuticals Inc. May Not Be In the Best Interest of SCLN Shareholders - June 14 at 12:47 AM logoSciClone to be Bought by China-Based Group - June 8 at 9:53 PM logoSciClone Announces Merger; Consortium To Acquire SciClone For $11.18/shr - June 8 at 9:53 PM logoSciclone Pharma (SCLN) Agrees to be Acquired by Consortium Led By GL Capital for $11.18/Share - June 8 at 9:53 PM logoSciClone To Present At Needham Healthcare... - March 27 at 9:17 AM logoSciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha - March 7 at 7:35 PM logoSciClone Reports 2016 Financial Results And 2017 Outlook - March 6 at 11:38 AM logoQ4 2016 SciClone Pharmaceuticals Inc Earnings Release - Before Market Open - March 6 at 11:38 AM logoSCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements - March 6 at 11:38 AM logoSCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fin - February 28 at 7:21 PM logoSCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers - January 6 at 9:50 PM



SciClone Pharmaceuticals (SCLN) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.